The power of precision
For every cancer patient
Today

Latest news
2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap
Read more

From Vision to Reality

The IVD market is the most heavily regulated in the world. Discover how we are navigating this complexity to turn our vision into reality…

More

2cureX Blog

The 2cureX Blog provides information on the IndiTreat® products, strategic developments in 2cureX and general information within the area of functional drug sensitivity testing of cancer patients

More

IndiTreat®

IndiTreat® is the first CE IVD-marked drug sensitivity test using 3D tumoroids, and delivers true precision in terms of treatment decisions for every cancer patient...

More

Press releases & news

  • May 15 | 2025

    2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap

    Read more
  • April 14 | 2025

    EARLY NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ)

    Read more
  • February 27 | 2025

    2cureX publishes interim report for the second half year of 2024

    Read more
  • January 20 | 2025

    2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE

    Read more
All press realeases & news

Latest report

Latest presentation

  • 2023-01-19

    2CUREX PRESENTS AT REDEYE FIGHT CANCER

Share Information

See our latest share information

Calendar & upcoming events

All events

Information for Oncologists and Pathologists

Know more when it matters most:
With our IndiTreat® tests you can finally obtain personalised information, even on the classic compounds for the main chemotherapy backbone for your stage IV mCRC patients.

More

Information for Patients

You’ve been diagnosed with colorectal cancer, and it is in stage IV. There are rational treatment choices to be made. Which therapy is more likely to impact the tumor? Ask your doctor about IndiTreat®.

More